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Abstract 
Background: Osteoarthritis (OA) is a common degenerative joint disorder that affects millions of people 
worldwide. It occurs when the cartilage or cushion between joints breaks down from “wear and tear” 
causing inflammation and symptoms such as pain, stiffness and swelling that can lead to chronic 
disability and functional impairment. The most common conventional treatment is non-steroidal anti-
inflammatory drugs (NSAIDs), but there are significant risks associated with their use. Recent studies 
have demonstrated curcumin, an extract of turmeric, to be just as safe and effective as ibuprofen in the 
reduction of pain and functional improvement but with fewer side effects. This review focuses on the 
efficacy and safety of curcumin compared with NSAIDs in the symptomatic treatment of osteoarthritis 
pain. 
Methods: An exhaustive search of available medical literature was performed using MEDLINE-Ovid, 
MEDLINE-PubMed, ClinicalKey, Web of Science, Google Scholar, and UpToDate. Keywords used included: 
curcumin, turmeric, osteoarthritis, arthritis, pain, inflammation, and NSAIDs. Relevant articles were 
assessed for quality using GRADE. 
Results: Three studies meeting inclusion criteria were used for this systematic review. In all three studies, 
the use of curcumin significantly decreased pain severity in patients with osteoarthritis, with symptoms 
improving within 4-6 weeks. Curcumin also decreased gastrointestinal adverse effects in all three studies. 
In two of the studies, patients taking curcumin reported an improved quality of life and decreased need of 
additional treatments. Curcumin also improved WOMAC scores in two of the studies. 
Conclusion: These studies give fair evidence for the use of curcumin as an effective and safe therapy for 
decreasing pain severity in patients with osteoarthritis. Curcumin can be used alternatively to or 
concomitantly with NSAIDs. Therefore, curcumin therapy could be implemented in clinical practice for the 
treatment of osteoarthritis. Further research using randomized trials with a larger population size and 
longer length of study needs to be conducted in order to determine the long-term efficacy of curcumin. 
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Abstract  
Background:​ Osteoarthritis (OA) is a common degenerative joint disorder that affects 
millions of people worldwide. It occurs when the cartilage or cushion between joints 
breaks down from “wear and tear” causing inflammation and symptoms such as pain, 
stiffness and swelling that can lead to chronic disability and functional impairment. The 
most common conventional treatment is non-steroidal anti-inflammatory drugs 
(NSAIDs), but there are significant risks associated with their use. Recent studies have 
demonstrated curcumin, an extract of turmeric, to be just as safe and effective as 
ibuprofen in the reduction of pain and functional improvement but with fewer side 
effects. This review focuses on the efficacy and safety of curcumin compared with 
NSAIDs in the symptomatic treatment of osteoarthritis pain.  
 
Methods:​ An exhaustive search of available medical literature was performed using 
MEDLINE-Ovid, MEDLINE-PubMed, ClinicalKey, Web of Science, Google Scholar, 
and UpToDate. Keywords used included: curcumin, turmeric, osteoarthritis, arthritis, 
pain, inflammation, and NSAIDs. Relevant articles were assessed for quality using 
GRADE.  
 
Results:​ Three studies meeting inclusion criteria were used for this systematic review. In 
all three studies, the use of curcumin significantly decreased pain severity in patients with 
osteoarthritis, with symptoms improving within 4-6 weeks. Curcumin also decreased 
gastrointestinal adverse effects in all three studies. In two of the studies, patients taking 
curcumin reported an improved quality of life and decreased need of additional 
treatments. Curcumin also improved WOMAC scores in two of the studies.  
 
Conclusion:​ These studies give fair evidence for the use of curcumin as an effective and 
safe therapy for decreasing pain severity in patients with osteoarthritis. Curcumin can be 
used alternatively to or concomitantly with NSAIDs. Therefore, curcumin therapy could 
be implemented in clinical practice for the treatment of osteoarthritis. Further research 
using randomized trials with a larger population size and longer length of study needs to 
be conducted in order to determine the long-term efficacy of curcumin.  
 
 
Keywords:​ curcumin, turmeric, osteoarthritis, arthritis, pain, inflammation and NSAIDS.  
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The Effects of Curcumin in Decreasing Pain in Patients with Osteoarthritis 
BACKGROUND  
Osteoarthritis (OA) is the most common degenerative joint disorder and a leading 
cause of chronic disability and functional impairment in the United States.​1​ It is a 
prevalent articulate disease that affects more than 27 million adults, making OA the 
fourth most global cause of disability in women and eighth most important in men.​2 
There are more than 100 different forms of arthritis most often affecting joints in 
the knees, hips, hands, and spine.​ ​Inflammation results from the breakdown of cartilage 
and fluid inside the joints causing severe pain. The severity of pain varies from person to 
person. Twenty-five percent of adults suffering with arthritis state that it causes severe 
pain (7 or higher on a 0 to 10 point scale).​3​ Pain can range from mild to immobilizing, 
negatively affecting the quality of life of individuals suffering from OA and also 
increasing their risk of morbidity and mortality.​2​ Non-steroidal anti-inflammatory drugs 
(NSAIDs) is the most common conventional pharmacologic treatment used for 
addressing pain associated with OA.​4​ However, some patients are unable to use NSAIDs 
due to their adverse effects on the gastrointestinal (GI) system and increased risk for 
cardiovascular disease.  
For individuals who suffer from OA pain and cannot tolerate NSAIDs or for those 
who prefer a more natural approach to treatment, they can consider using Turmeric.​2 
Turmeric is a member of the ginger family (Zingiberaceae), an ancient herb native to 
Southern Asia. The primary active constituent of turmeric is curcumin (​syn. Curcumin 
domestica​). It gives turmeric its’ vibrant yellow-orange color and sharp flavor, making it 
 
 one of the principle spices used in oriental food and curry dishes. Curcumin has been 
used in holistic medicine for its’ anti-inflammatory, antioxidant, and antimicrobial 
properties. It has a long history of use in Ayurvedic, herbal, and traditional Chinese 
medicine.​5​ According to the New York University Langone Medical Center, 400-600 
milligrams of curcumin taken 3 times per day is needed to see therapeutic benefits.​6 
Because curcumin exists in less than 5% in turmeric spice, ​ ​a significant amount needs to 
be consumed in order to potentially improve health.​7 ​Curcumin supplements have been 
proven to provide therapeutic levels and can be used at 2000 mg/day for up to 6 weeks or 
a higher dose up to 8000 mg/day for 3 months without any serious adverse events.​2,8 
Compared to NSAIDs, curcumin has notable advantages in the treatment of 
inflammatory conditions such as osteoarthritis.​2​ Curcumin selectively inhibits the activity 
of cyclooxygenase (COX-2), reducing the prostaglandins which contribute to 
inflammation by promoting vasodilation and increasing vascular permeability. Curcumin 
also inhibits the production of inflammatory cytokines such as interferon interleukins, 
tumor necrosis factor, nitric oxide synthase enzymes, and activation of NF-kB.​1​ The role 
of curcumin in modulating the inflammatory process and all of these substances provides 
a more natural and therapeutic treatment for OA as long as it is as effective as NSAIDs in 
managing pain.​2​ This review focuses on the efficacy and safety of curcumin compared 
with NSAIDs in the symptomatic treatment of osteoarthritis pain. 
METHODS  
An exhaustive search of available medical literature was performed using 
MEDLIN-Ovid, MEDLINE-PubMed, ClinicalKey, Web of Science, Google Scholar, and 
 
 UpToDate. Keywords used included: curcumin, turmeric, osteoarthritis, arthritis, pain, 
inflammation, and NSAIDS. The search was narrowed to include English language 
articles and human trials only. The bibliographies of the articles were further searched for 
relevant sources. Relevant articles were assessed for quality using Grading of 
Recommendations, Assessment, Development and Education (GRADE).​9 
RESULTS  
Three studies meeting inclusion criteria were used for this systematic review. One 
of the studies was an observational study​10​ and two were controlled studies.​2,11​ See Table 
I for quality assessment of each article using GRADE criteria.  
 
Kuptniratisaikul et al (​Curcuma ​do​mestica​ extracts compared with ibuprofen)  
In this double-blind randomized control study,​2​ 367 patients with primary knee 
osteoarthritis age ≥ 50 years from July 2010 to March 2012 were included. The 
randomization number was generated by computerized method and allocated 185 patients 
to receive 1200 mg/day of ibuprofen and 182 patients to recei​ve 1500 mg/day of ​C. 
domestica​ extracts. For blinding both patients and assessors, medications were 
manufactured to be identical capsules in appearance. Treatment codes were kept from the 
pharmacist who was not involved in the study. Patients were instructed to take two 
capsules after meals 3 times a day for 4 weeks. Outcomes were evaluated at week 2 and 
week 4 by the same assessor at each site. The inclusion criteria were primary knee OA 
according to the American Rheumatism Association criteria who had a numerical rating 
scale of knee pain of 5 out of 10 and age ≥ to 50 years. Patients who had abnormal liver 
 
function or renal function, history of peptic ulcer, allergy to curcmin or ibuprofen, or 
were unable to walk were excluded.​2 
After being recruited, participants received a knee X-ray, which indicated the 
severity (II–IV grading) according to Kellgren–Lawrence criteria. The outcomes were 
measured using the Western Ontario and McMaster Universities Osteoarthritis Index 
(WOMAC). The WOMAC scores were composed of 3 subscales: pain, stiffness, and 
function. Each scale ranged from 0 to 1​0; hi​gher scores represented more pain, more 
stiffness, or worse knee functions. A 6-minute walk distance was also compared between 
groups at week 4. For safety concerns, the adverse effects were recorded if patients 
experienced new symptoms during the study. Compliance of treatment was determined at 
each visit by the pill count. Lastly, global assessment and satisfaction of each patient was 
evaluated at the end of the study.​2 
This study was designed as a noninferiority trial with the assumption that there 
was a significant difference of ±0.5 points in the WOMAC pain score after treatment. To 
compare the WOMAC mean scores and the 6-minute walk distance between groups, 
analysis of covariance and the unpaired ​t​-test for noninferiority and equality were used. 
Chi-square test was used to analyze the AEs, satisfaction level​s, a​nd compliance of drug 
intake was measured using the ​t​-test for equality.​2  
Baseline characteristics of participants were the same between groups with the 
mean age of 60 years, approximately 90% female, and a body mass index of of 26 kg/m​2​. 
Nearly 60% of participants had unilateral knee pain. At baseline, both groups had 
WOMAC scores greater than 5 out of 10.  The 6-minute walk distance was 304 meters 
 
and 310 meters in the ibuprofen and​ C. domestica​ extracts groups, respectively. The 
numbers of knee X-rays with grading classified by Kellgren–Lawrence criteria were 138 
(86.8%) versus (vs) 150 (87.7%) in the ibuprofen and ​C. domestica​ extracts groups, 
respectively, same in both groups.​2 
The changes over time of ​C. domestica​ and ibuprofen were measured at week 0, 
4, and 6 using the WOMAC index. A within-group comparison showed decreased 
WOMAC scores in both groups (P-value < 0.001), which meant significant improvement 
from baseline. However, a between-group comparison showed no difference in WOMAC 
total score (P-value 0.326), WOMAC pain ( (P-value 0.531), or WOMAC function 
(P-value 0.278).  In addition, the 6-minute walk distance at week 4 was approximately 
350 meters with no difference between groups (mean difference and 95% CI were 7.18 
meters and -7.01 to 21.38 meters).​2 
During the study, common AEs included dyspepsia, abdominal pain/distension, 
nausea, loose stool, and pitting edema. The number of participants that developed AEs 
during the study was not different between the two groups (P value 0.222). Symptoms of 
loose stool was higher in the ​C. domestica​ extracts group than in the ibuprofen group but 
with no significant difference (P-value 0.330). For the numbers of events that occurred, 
the rate of abdominal pain/distension was significantly lower in the ​C. domestica​ extracts 
group than in the ibuprofen group (P-value 0.046).​2 
There was no difference between groups in drug compliance (P-value 0.202) 
including the patient’s global assessment and satisfaction that was measured between 
groups at week 4 (P-value 0.665 and P-value 0.707, respectively). Overall, about 97% of 
 
participants were satisfied with the treatment and two-thirds rated themselves as 
improved in a global assessment.​2 
A total of 160 patients in the ibuprofen and 171 in the​ C. domestica​ extract groups 
completed the study. The reasons for being lost to follow up included withdrawal, 
inconvenience, participants unable to be contacted, and adverse effects (seven patients in 
the ibuprofen and one patient in the ​C. domestica​ group).​2 
Appelboom et al (Flexofytol Study)  
An observational study​10​ was performed in 2013 with the help of general 
physicians in evaluating the potential benefits of Flexofytol (which contains curcumin 
extract as its main active ingredient) on joint function, pain severity, flexibility, and 
quality of life of their patients. There were 110 general practitioners from Belgium who 
participated in the study and followed 820 patients treated with Flexofytol for a 6-month 
duration. Physicians were asked to report the effects of Flexofytol, including: number of 
joints affected, pain intensity (0 = no pain to 10 = intolerable pain), joint flexibility (0 = 
bad to 10 = excellent), and quality of life (visual scale of 0 = bad to 10 = excellent). 
Global evaluation of the efficacy of treatment according to the patient, use of 
concomitant treatments, undesirable effects and patients’ desire to continue or 
discontinue the treatment was also measured.​10 
In total, 820 patients suffering from OA (36.7% men) with a mean age of 64.2 +/- 
12.4 years were followed and evaluated by their physicians after 6 weeks, 3 months, and 
6 months of treatment. There were 739 patients who were using 2 capsules two times 
daily and 81 patients took 2 capsules three times daily to improve joint function. Of the 
 
total patients, 563 of them reported suffering unilateral joint pain, mainly knee and the 
lower back, and 67 patients suffered from at least 3 locations. Before stating Flexofytol, 
most patients (85%) were treated with NSAIDs, analgesic agents (64.7%) and/or 
chondroprotective agents (13.4%). Global evaluation of efficacy of treatment, use of 
concomitant treatment, AEs, and patient’s desire to continue or discontinue treatment 
were also ascertained. The General Linear Model Method was used to analyze pain, 
mobility, and quality of life, and differences were considered statistically significant at 
p<0.05.​10 
Improvements were reported within the first 6 weeks of Flexofytol treatment. 
Most patients reported a decrease in pain (6.9 to 3.2, p<0.0001), a significant increase in 
flexibility (4.2 to 6.7, p<0.001), better quality of life (4.7 to 6.9, p<0.0001) and a 
reduction in the amount of concomitant therapies used (p<0.001). Gastrointestinal side 
effects such as diarrhea were reported by 3.6% of patients at 6 weeks, 2.5% at 3 months, 
and 1.3% at 6 months. Global assessments provided by patients confirmed 77.1% were 
satisfied with Flexofytol at 6 weeks and 79% were still satisfied at 6 months. At 6 
months, 41.7% of patients wished to continue using Flexofytol, 10.8% responded 
negatively, and 47.5% had no opinion for continuing for a longer period.​10 
 
Belcaro et al (Meriva Study) 
In an 8-month study,​11 ​researchers evaluated the efficacy and safety of Meriva, a 
curcumin-phosphatidylcholine phytosome complex. The study involved 100 patients with 
symptomatic osteoarthritis. The inclusion criteria included patients who with grade 1 or 2 
 
knee osteoarthritis (one or both knees) following the American Rheumatism Association 
grading scale and diagnosed via X-ray. The exclusion criteria included patients with 
“cardiovascular disease requiring drug treatment, diabetes, body mass index >25, severe 
metabolic disorders, surgery or arthroscopy within 3 months prior to inclusion, any 
oncological condition, or severe bone or joint deformation or condition making the 
patient unable to walk…pregnancy, breast feeding, and planned conception.” 
Participants were required to perform a treadmill-walking test and be able to fill out a 
WOMAC questionnaire.​11 
Patients were either given NSAIDs alone (control group), or a combination of 
NSAIDs and curcumin (treatment group). Patients in the treatment group were given two 
500 mg tablets daily, one after breakfast and one after dinner, for a total of 1000 mg a 
day. Results were recorded at enrollment and at 8 months.​11 
Five patients in the treatment group and six in the control group left the study 
early for non-medical reasons including moving and work problems.​11 
The Kanofsky Performance Scale was used to measure functional impairment. 
Lower scores corresponded with greater functional impairment. Functional ability 
improved significantly in the treatment group from 73.3 at enrollment to 92.2 at 8 
months, with no significant improvement in the control group.​11 
 The WOMAC questionnaire was used to evaluate symptoms using a score range 
for pain (0-20), stiffness (0-8), and physical function (0-68). Higher scores corresponded 
with greater pain, stiffness, and physical function. All WOMAC scores showed 
significant improvement at 8 months in the treatment group compared to the control 
 
 group (p<0.05). Pain dropped significantly in the treatment group from 16.6 (at 
enrollment) to 7.3 (at 8 months), compared to 16 to 15.2 in the control group. Stiffness 
also reduced significantly from 7.4 to 3.2 in the treatment group compared to 6.6 to 6.7 in 
the control group. The total WOMAC score in the treatment group decreased 
significantly from 80.6 to 33.3 compared to the control group, which slightly decreased 
from 77.8 to 68.8.​11 
 The treadmill test was used to evaluate physical performance. A speed of 3 km/h 
with an inclination of 10% was used, and the total distance achieved by patients was 
documented at enrollment and 8 months. Patients taking Meriva were able to achieve a 
significantly greater total distance on the treadmill test at the end of the study (increased 
from 77.3 meters at enrollment to 344.4 meters at 8 months) compared to the control 
group (increased from 82.3 meters to 156 meters). This corresponds to a 345% (3.87 
times greater) improvement in the treatment group at 8 months compared to an 89% 
increase in the control group.​11 
 There was a 63% decrease in the use of NSAIDs or other painkillers in the 
treatment group compared to a 12% decrease in the control group. Meriva patients had a 
49% decrease in management costs compared to 3% in controls.​11 
DISCUSSION  
Osteoarthritis is a chronic disabling disease requiring lifelong treatment. NSAIDs 
are currently the standard of care used to treat the symptoms associated with OA. 
Considering the gastrointestinal and cardiovascular adverse effects caused by the use of 
NSAIDs, a more natural option for treatment of osteoarthritis should be sought. This 
 
evidence suggests that curcumin can be used as an alternative or in addition to NSAIDs 
for decreasing pain in patients with osteoarthritis.​2,10,11 ​These studies have also shown that 
curcumin can improve physical function, flexibility, and quality of life. The studies have 
shown that curcumin can be effective at as early as 4-6 weeks of treatment for decreasing 
pain.​2,10,11​ Evidence from the three studies used in this review confirm the safety and 
analgesic efficacy of curcumin as a natural therapeutic option for patients with 
osteoarthritis. 
In addition to the health benefits of curcumin, evidence shows the use of 
curcumin to be cost effective. In the study by Belcaro et al,​11​ individuals taking Meriva 
had a 49% decrease in management costs compared to 3% in the control group.​ ​Patients 
with OA require lifelong treatment, therefore decreasing management costs can lessen 
their financial burden. The study also showed a 63% decrease in the use of NSAIDs or 
other painkillers in the treatment group compared to a 12% decrease in the control group. 
In the study by Kuptniratsaikul et al,​2​ there were no significant differences in results 
(non-inferiority test) between ibuprofen and ​C. domestica​ for the WOMAC scores and 
6-minute walk test. This suggests that ​C. domestica​ extracts are as efficacious as 
ibuprofen in pain reduction and functional improvement, with ​C.domestica​ extracts 
showing a better safety profile than ibuprofen in terms of abdominal pain and distension.  
The study conducted by Appelboom et al​10​ showed anti-inflammatory effects of 
Flexofytol within 6 weeks of treatment, showing a decrease in inflammatory mediators at 
6 months: interleukin 1B, interleukin 6, the ligand of CD40, and decrease in blood 
sedimentation rate. Flexofytol is a new curcumin formulation that can be used to combat 
 
the low oral bioavailability of curcumin. Flexofytol has a polyphenol structure that makes 
it 1350 times more assimilable than native curcumin powder, allowing it to penetrate 
tissues more easily and remain relatively stable in the intestines. A dose of 42 mg of 
Flexofytol is equivalent to 57 g of native curcumin or 1 kg of curcuma powder.  While 
the analgesic effects of Flexofytol were observed in all joints, it was most noticeably in 
the knee and hip joints. The study​10 ​reported high patient satisfaction and a decrease in 
concomitant therapies after six months of therapy with Flexofytol. 
The three studies used in this review have all shown that curcumin has an 
analgesic effect on osteoarthritic joints; however, there are some limitations. In the study 
by Belcaro et al,​11​ the study did not directly compare Meriva against NSAIDs in a 
head-to-head comparison. The study was only 8 months, which may make it difficult to 
determine the long-term efficacy of Meriva. The mean age of the participants was 44, 
which is relatively young. Another thing worth noting is that Meriva has low 
bioavailability; however, studies have suggested that consuming pepper or piperidine 
with the curcumin tablets can help increase the oral bioavailability of curcumin.​2​ The 
study conducted by Kuptniratsaikul et al​2​ consisted of participants who were all Thai 
females. In the study, researchers had to adjust the max daily ibuprofen levels to a lower 
dose of 1200 mg/day from the normal 1800 mg/day because Thai individuals have a 
lower mean body weight compared to Caucasians. One of the limitations of the study by 
Appelboom et al​10​ is that it lacks a control group. 
Based on the results of these three studies, the use of curcumin as an analgesic is 
supported in patients with osteoarthritis. However, the length of these studies did not 
 
 exceed 8 months, therefore, further research with a longer length of study should be 
conducted in order to determine the long-term efficacy and potential adverse side effects 
of curcumin. Only one of the studies that was reviewed directly compared curcumin to 
NSAIDs. More research directly comparing the efficacy and safety of curcumin to 
NSAIDs is needed to confirm if curcumin can be used as a replacement for NSAIDs in 
decreasing pain severity in patients with osteoarthritis. Research evaluating the efficacy 
of curcumin at different doses and determining the maximum dose of efficacy should also 
be conducted, as this may be beneficial for health care providers who are treating patients 
with different severity levels. 
 
CONCLUSION  
Curcumin is an effective and safe natural option for decreasing pain severity and 
improving quality of life in patients with osteoarthritis. Curcumin can be used as an 
alternative to NSAIDs or concomitantly across the lifespan. Curcumin therapy should be 
implemented in clinical practice for the treatment of osteoarthritis. Further research using 
randomized trials with a larger population size and longer length of study needs to be 
conducted in order to determine the long-term efficacy of Curcumin. Moreover, research 
investigating the direct comparison of Meriva to NSAIDs would be of value in 
determining the efficacy of Meriva, and whether it can be used as an alternative to 
NSAIDs.  
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Table  
 
Table 1: Quality Assessment of Reviewed Articles 
Study Design Downgrade Criteria Upgrade 
Criteria 
Quality 
Limitations Indirectness Inconsist
ency 
Impreci
sion 
Publicatio
n bias 
Kuptniratsaikul 
et al 
RCT Not Serious Not Serious Not 
Serious 
Not 
Serious 
Unlikely None High 
Appelboom et al Observ
ational 
Serious​a Not Serious Not 
Serious 
Not 
Serious 
Unlikely None Very 
Low 
Belcaro et al Observ
ational 
Not Serious Not Serious Not 
Serious 
Serious​b Unlikely None Very 
Low 
a ​Lacked a control group 
b ​Small sample size 
 
 
